the official website of the antibody society
The Antibody Society
Antibody Engineering & Therapeutics commences on Thursday, December 14, 2023! Visit us at Booth #113 for a free T shirt and networking.
And don’t miss the keynote address by Dr. Heather Bax, the 2023 Huston Award recipient.
The last AIRR-C webinar “Quality Control Pipelines for T cell and B cell AIRR-seq”, by Dr. Encarnita Mariotti-Ferrandiz (Sorbonne Universite) and Dr. Nina Luning Prak (University of Pennsylvania) is now available online.
Visit the AIRR Community Webinar Series website to learn more about this series and access the recordings of past sessions.
Explore with us the state-of-the-art in TCR-Epitope prediction. T-cells are at the heart of the immune system’s ability to distinguish between self and non-self, playing a critical role in both health and disease. Given the sheer scale of potential TCR-epitope interactions (stemming from both the enormous epitope and TCR repertoire diversity) experimental validation of each TCR interaction is not feasible. This has spurred the development of TCR-epitope prediction models that aim to narrow down the search for immunogenic epitopes, thereby streamlining research and reducing costs. Our webinar “Exploring TCR-Epitope Prediction Tools: Insights and Pitfalls” will delve into these predictive strategies, highlighting their importance in advancing immunological research and applications.
Speakers:
All three researchers are working under the supervision of Prof. Pieter Meysman, Prof. Kris Laukens, and Prof. Benson Ogunjimi at the University of Antwerp in Belgium.
Registration is open. Visit the AIRR Community Webinar Series website to learn more about this series and access the recordings of past sessions.
The November AIRR-C seminar is fast approaching! On November 30th at 7:00 PST/10:00 EST/16:00 CET, Aaron Michels of the University of Colorado Anschutz Medical Campus will be presenting “Temporal Development of T cell receptor Repertoires during Childhood in Health and Type 1 Diabetes” and Julien Limenitakis of the University of Bern will be presenting “Diet and Microbiota effects on the B cell repertoire”.
Register now! The seminar will last approximately 90 minutes.
Visit the AIRR Community Seminar Series website to learn more about this series and access the recordings of past sessions.
On November 17, 2023, Almirall S.A. announced that the European Commission approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Lebrikizumab (Ebglyss) is a humanized, hinge-stabilized (S228P mutation) IgG4k antibody that targets IL-13, a key mediator of the pro-inflammatory response and enhances neuronal responses to the persistent itch stimuli in atopic dermatitis.
The approval in the European Union is based on results from three phase 3 trials evaluating the safety and efficacy of lebrikizumab in adults and adolescents >12 years of age with atopic dermatitis. Advocate 1 (NCT04146363) and Advocate 2 (NCT04178967) are randomized, double-blind, placebo-controlled, parallel-group studies in which patients with moderate-to-severe atopic dermatitis received either an initial dose of 500 mg of lebrikizumab followed by 250 mg lebrikizumab Q2W, or placebo for a 16-week treatment period. Following the 16 weeks, patients who received a clinical response to lebrikizumab were re-randomized to receive lebrikizumab Q2W or Q4W, or placebo, for another 36 weeks. The primary endpoints were an Investigator Global Assessment (IGA) score of clear or almost clear (0 or 1, respectively) skin with reduction of at least two points from baseline and at and least 75% reduction in the Eczema Area and Severity Index (EASI-75) score. Both Advocate 1 and Advocate 2 met their primary endpoints, with the IGA outcome being achieved in 43.1% of the lebrikizumab cohort (n=283) compared to 12.7% in placebo cohort (n=141) for Advocate 1, and 33.2% of the lebrikizumab cohort (n=281) compared to 10.8% in the placebo cohort (n=146) for Advocate 2. [1] The third Phase 3 study, Adhere (NCT04250337), is a 16-week randomized, double-blind, parallel-group study which investigated the efficacy of lebrikizumab in combination with topical corticosteroids in 211 patients with AD. Patients were randomized 2:1 to receive either 250mg SC lebrikizumab Q2W after an initial loading dose of 500 mg, or placebo, in combination with topical steroids, either mid-potency (0.1% triamcinolone acetonide cream) or low-potency (1% hydrocortisone cream). After 16 weeks, IGA of 0 or 1 with a 2 or more-point reduction from baseline was achieved by 41.2% of the lebrikizumab cohort compared to 22.1% of the placebo cohort, with statistical significance being reached as early as 8 weeks. [2] There was also a significantly greater proportion of patients achieving EASI-75 responses.
Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe. Eli Lilly and Company has exclusive rights for the development and commercialization of the product in the United States and the rest of the world, not including Europe. Lilly has submitted a marketing application for lebrikizumab for atopic dermatitis to the US Food and Drug Administration.
